Dysregulation of MiR-21, MiR-221 and MiR-451 During Neoadjuvant Treatment of Breast Cancer: A Prospective Study
Carine Bispo Patury, Brenda Luanny Maia Santos, Anna Lucia Carvalho Matos, José Slabi, Luciene Cristina Campos Gastalho, Carla Martins Kaneto · 2024
Read Dysregulation of MiR-21, MiR-221 and MiR-451 During Neoadjuvant Treatment of Breast Cancer: A Prospective Study by Carine Bispo Patury, Brenda Luanny Maia Santos, Anna Lucia Carvalho Matos, José Slabi, Luciene Cristina Campos Gastalho, Carla Martins Kaneto (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11674781.txt.
Description
Carine Bispo Patury and five co-authors track three tiny RNA molecules through breast cancer chemotherapy in this 2024 study. The molecules are microRNAs, short regulators that circulate in blood and may serve as cancer markers. The team followed women in Brazil receiving neoadjuvant treatment, chemotherapy given before surgery, and compared them with cancer-free controls.
Twenty-seven patients and thirty-three controls took part. Most tumors were locally advanced, and the group spanned the main breast cancer subtypes. Two of the markers, miR-21 and miR-221, climbed by the end of treatment, while a third, miR-451, ran high from the start. A fourth marker, miR-195, showed no clear pattern. The authors call the three shifting molecules deregulated by treatment and suggest they could help monitor therapy. They note the study is the first of its kind in a Brazilian population.
Catalog record
| CREATOR | Carine Bispo Patury, Brenda Luanny Maia Santos, Anna Lucia Carvalho Matos, José Slabi, Luciene Cristina Campos Gastalho, Carla Martins Kaneto |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |